Aptalis Holdings Inc.
Aptalis Holdings Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has established itself as a leader in developing innovative drug delivery systems and specialty pharmaceuticals. With a focus on enhancing patient outcomes, Aptalis operates primarily in North America and Europe, catering to diverse therapeutic areas, including gastrointestinal and respiratory health.
The company’s core offerings include advanced formulations and unique delivery technologies that set them apart in a competitive market. Notable achievements include strategic partnerships and a robust pipeline of products that address unmet medical needs. Aptalis Holdings Inc. continues to solidify its market position through a commitment to research and development, driving advancements in patient care and therapeutic efficacy.
-4 vs industry average
Aptalis Holdings Inc.’s score of 34 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Aptalis Holdings Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Aptalis Holdings Inc. yet.
Aptalis Holdings Inc.'s reported carbon emissions
Aptalis Holdings Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which influences its climate commitments and reporting practices.
While Aptalis Holdings Inc. does not have its own documented reduction targets, it inherits sustainability initiatives from its parent company, AbbVie Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions in line with global climate goals.
As part of its corporate family, Aptalis may also align with broader climate strategies and commitments established by AbbVie, which are designed to enhance environmental performance and accountability. However, specific details regarding Aptalis's individual climate pledges or reduction targets remain unspecified.
In summary, while Aptalis Holdings Inc. does not provide direct emissions data or specific reduction targets, it is positioned within a corporate structure that prioritises climate action through inherited initiatives from AbbVie Inc.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Aptalis Holdings Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Aptalis Holdings Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from AbbVie Inc.
Carbon Disclosure Project
Inherited from AbbVie Inc.
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project